##gff-version 3
##sequence-region O14746 1 1132
O14746	UniProtKB	Chain	1	1132	.	.	.	ID=PRO_0000054925;Note=Telomerase reverse transcriptase	
O14746	UniProtKB	Domain	605	935	.	.	.	Note=Reverse transcriptase;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00405	
O14746	UniProtKB	Region	1	230	.	.	.	Note=RNA-interacting domain 1	
O14746	UniProtKB	Region	58	197	.	.	.	Note=GQ motif	
O14746	UniProtKB	Region	137	141	.	.	.	Note=Required for regulating specificity for telomeric DNA and for processivity for primer elongation	
O14746	UniProtKB	Region	231	324	.	.	.	Note=Linker	
O14746	UniProtKB	Region	301	538	.	.	.	Note=Required for oligomerization	
O14746	UniProtKB	Region	325	550	.	.	.	Note=RNA-interacting domain 2	
O14746	UniProtKB	Region	376	521	.	.	.	Note=QFP motif	
O14746	UniProtKB	Region	397	417	.	.	.	Note=CP motif	
O14746	UniProtKB	Region	914	928	.	.	.	Note=Required for oligomerization	
O14746	UniProtKB	Region	930	934	.	.	.	Note=Primer grip sequence	
O14746	UniProtKB	Region	936	1132	.	.	.	Note=CTE	
O14746	UniProtKB	Motif	222	240	.	.	.	Note=Bipartite nuclear localization signal	
O14746	UniProtKB	Motif	328	333	.	.	.	Note=TFLY%3B involved in RNA binding;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q4KTA7	
O14746	UniProtKB	Metal binding	712	712	.	.	.	Note=Magnesium%3B catalytic;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00405	
O14746	UniProtKB	Metal binding	868	868	.	.	.	Note=Magnesium%3B catalytic;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00405	
O14746	UniProtKB	Metal binding	869	869	.	.	.	Note=Magnesium%3B catalytic;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00405	
O14746	UniProtKB	Site	169	169	.	.	.	Note=Required for optimal binding of telomeric ssDNA and incorporation of nucleotides at the second position of the template	
O14746	UniProtKB	Site	867	867	.	.	.	Note=Required for nucleotide incorporation and primer extension rate	
O14746	UniProtKB	Modified residue	227	227	.	.	.	Note=Phosphoserine%3B by PKB/AKT1;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:22366458;Dbxref=PMID:22366458	
O14746	UniProtKB	Modified residue	457	457	.	.	.	Note=Phosphoserine%3B by DYRK2;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23362280;Dbxref=PMID:23362280	
O14746	UniProtKB	Modified residue	707	707	.	.	.	Note=Phosphotyrosine%3B by SRC-type Tyr-kinases;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12808100,ECO:0000269|PubMed:18829466;Dbxref=PMID:12808100,PMID:18829466	
O14746	UniProtKB	Alternative sequence	711	722	.	.	.	ID=VSP_053369;Note=In isoform 4. Missing;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:14654914;Dbxref=PMID:14654914	
O14746	UniProtKB	Alternative sequence	764	807	.	.	.	ID=VSP_019587;Note=In isoform 2 and isoform 4. STLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFD->LRPVPGDPAGLHPLHAALQPVLRRHGEQAVCGDSAGRAAPAFGG;Ontology_term=ECO:0000303,ECO:0000303;evidence=ECO:0000303|PubMed:12869302,ECO:0000303|PubMed:14654914;Dbxref=PMID:12869302,PMID:14654914	
O14746	UniProtKB	Alternative sequence	808	1132	.	.	.	ID=VSP_019588;Note=In isoform 2 and isoform 4. Missing;Ontology_term=ECO:0000303,ECO:0000303;evidence=ECO:0000303|PubMed:12869302,ECO:0000303|PubMed:14654914;Dbxref=PMID:12869302,PMID:14654914	
O14746	UniProtKB	Alternative sequence	885	947	.	.	.	ID=VSP_021727;Note=In isoform 3. Missing;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:14654914;Dbxref=PMID:14654914	
O14746	UniProtKB	Natural variant	55	55	.	.	.	ID=VAR_062535;Note=In idiopathic pulmonary fibrosis susceptibility%3B impaired telomerase activity. L->Q;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17392301;Dbxref=dbSNP:rs387907247,PMID:17392301	
O14746	UniProtKB	Natural variant	65	65	.	.	.	ID=VAR_062780;Note=Associated with acute myeloid leukemia. P->A;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:19147845,ECO:0000269|PubMed:19760749;Dbxref=dbSNP:rs544215765,PMID:19147845,PMID:19760749	
O14746	UniProtKB	Natural variant	170	170	.	.	.	ID=VAR_068792;Note=In PFBMFT1%3B the mutant protein is demonstrated to cause decreased telomerase activity. V->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:21436073;Dbxref=dbSNP:rs387907248,PMID:21436073	
O14746	UniProtKB	Natural variant	202	202	.	.	.	ID=VAR_036863;Note=In PFBMFT1 and AA%3B severe and moderate%3B associated with disease susceptibility%3B shorter telomeres. A->T;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15814878,ECO:0000269|PubMed:15885610,ECO:0000269|PubMed:19760749;Dbxref=dbSNP:rs121918661,PMID:15814878,PMID:15885610,PMID:19760749	
O14746	UniProtKB	Natural variant	279	279	.	.	.	ID=VAR_036864;Note=A->T;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15814878;Dbxref=dbSNP:rs61748181,PMID:15814878	
O14746	UniProtKB	Natural variant	299	299	.	.	.	ID=VAR_062781;Note=Associated with acute myeloid leukemia. V->M;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:19147845,ECO:0000269|PubMed:19760749;Dbxref=dbSNP:rs756624928,PMID:19147845,PMID:19760749	
O14746	UniProtKB	Natural variant	412	412	.	.	.	ID=VAR_025149;Note=In PFBMFT1%2C AA and DKCB4%3B severe and moderate%3B associated with susceptibility to acute myelogenous leukemia%3B the mutant protein has 36%25 residual activity. H->Y;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15814878,ECO:0000269|PubMed:18042801,ECO:0000269|PubMed:19147845,ECO:0000269|PubMed:19760749,ECO:0000269|Ref.7;Dbxref=dbSNP:rs34094720,PMID:15814878,PMID:18042801,PMID:19147845,PMID:19760749	
O14746	UniProtKB	Natural variant	441	441	.	.	.	ID=VAR_036865;Note=In AA%3B associated with susceptibility to acute myeloid leukemia. Missing;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15814878,ECO:0000269|PubMed:19147845,ECO:0000269|PubMed:19760749;Dbxref=PMID:15814878,PMID:19147845,PMID:19760749	
O14746	UniProtKB	Natural variant	522	522	.	.	.	ID=VAR_062782;Note=Associated with acute myeloid leukemia. R->K;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:19147845,ECO:0000269|PubMed:19760749;Dbxref=PMID:19147845,PMID:19760749	
O14746	UniProtKB	Natural variant	570	570	.	.	.	ID=VAR_062536;Note=In AA%3B abolishes telomerase catalytic activity but no effect on binding to TERC. K->N;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:16990594,ECO:0000269|PubMed:19760749;Dbxref=PMID:16990594,PMID:19760749	
O14746	UniProtKB	Natural variant	631	631	.	.	.	ID=VAR_062783;Note=In AA. R->Q;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19760749;Dbxref=dbSNP:rs199422294,PMID:19760749	
O14746	UniProtKB	Natural variant	682	682	.	.	.	ID=VAR_062537;Note=In AA%3B non-severe%3B abolishes telomerase catalytic activity but little effect on binding to TERC. G->D;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:16627250,ECO:0000269|PubMed:16990594;Dbxref=dbSNP:rs199422295,PMID:16627250,PMID:16990594	
O14746	UniProtKB	Natural variant	694	694	.	.	.	ID=VAR_036866;Note=In PFBMFT1 and AA%3B moderate. V->M;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15814878,ECO:0000269|PubMed:19760749;Dbxref=dbSNP:rs121918662,PMID:15814878,PMID:19760749	
O14746	UniProtKB	Natural variant	704	704	.	.	.	ID=VAR_068793;Note=In DKCB4%3B the mutant protein has 13%25 residual activity. P->S;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:18042801,ECO:0000269|PubMed:21602826;Dbxref=dbSNP:rs199422297,PMID:18042801,PMID:21602826	
O14746	UniProtKB	Natural variant	716	716	.	.	.	ID=VAR_068794;Note=In PFBMFT1%3B the mutant protein is demonstrated to cause severely compromised telomerase activity. A->T;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:21436073;Dbxref=dbSNP:rs387907249,PMID:21436073	
O14746	UniProtKB	Natural variant	721	721	.	.	.	ID=VAR_062538;Note=In DKCB4%3B no effect on telomerase catalytic activity and little effect on binding to TERC. P->R;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:16332973,ECO:0000269|PubMed:16990594;Dbxref=dbSNP:rs199422299,PMID:16332973,PMID:16990594	
O14746	UniProtKB	Natural variant	726	726	.	.	.	ID=VAR_062539;Note=In AA%3B very severe%3B no effect on telomerase catalytic activity but shortened telomeres. T->M;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:16627250,ECO:0000269|PubMed:16990594;Dbxref=dbSNP:rs149566858,PMID:16627250,PMID:16990594	
O14746	UniProtKB	Natural variant	772	772	.	.	.	ID=VAR_036867;Note=In PFBMFT1%3B moderate. Y->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15814878;Dbxref=dbSNP:rs121918663,PMID:15814878	
O14746	UniProtKB	Natural variant	785	785	.	.	.	ID=VAR_062784;Note=In AA. P->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19760749;Dbxref=dbSNP:rs483352771,PMID:19760749	
O14746	UniProtKB	Natural variant	791	791	.	.	.	ID=VAR_068795;Note=In PFBMFT1%3B associated with Met-867 in cis on the same allele%3B the double mutant shows severe defects in telomere repeat addition processivity. V->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:21483807;Dbxref=dbSNP:rs141425941,PMID:21483807	
O14746	UniProtKB	Natural variant	811	811	.	.	.	ID=VAR_062540;Note=In DKCB4%3B 50%25 reduction in telomerase activity. R->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17785587;Dbxref=dbSNP:rs199422301,PMID:17785587	
O14746	UniProtKB	Natural variant	841	841	.	.	.	ID=VAR_068796;Note=In PFBMFT1. L->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:21436073;Dbxref=PMID:21436073	
O14746	UniProtKB	Natural variant	865	865	.	.	.	ID=VAR_036868;Note=In PFBMFT1. R->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17460043;Dbxref=dbSNP:rs121918666,PMID:17460043	
O14746	UniProtKB	Natural variant	867	867	.	.	.	ID=VAR_068797;Note=In PFBMFT1%3B associated with Ile-791 in cis on the same allele%3B the double mutant shows severe defects in telomere repeat addition processivity%3B this mutation causes most if not all of the functional defects. V->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:21483807;Dbxref=dbSNP:rs201159197,PMID:21483807	
O14746	UniProtKB	Natural variant	901	901	.	.	.	ID=VAR_062541;Note=In DKCB4%3B severe phenotype overlapping with Hoyeraal-Hreidarsson syndrome%3B very short telomeres and greatly reduced telomerase activity. R->W;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17785587;Dbxref=dbSNP:rs199422304,PMID:17785587	
O14746	UniProtKB	Natural variant	902	902	.	.	.	ID=VAR_036869;Note=In DKCA2%3B abolishes telomerase catalytic activity but no effect on binding to TERC. K->N;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:16247010,ECO:0000269|PubMed:16990594;Dbxref=dbSNP:rs121918665,PMID:16247010,PMID:16990594	
O14746	UniProtKB	Natural variant	902	902	.	.	.	ID=VAR_068798;Note=In PFBMFT1. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:21436073;Dbxref=dbSNP:rs387907250,PMID:21436073	
O14746	UniProtKB	Natural variant	923	923	.	.	.	ID=VAR_068799;Note=In PFBMFT1. P->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:22512499;Dbxref=dbSNP:rs387907251,PMID:22512499	
O14746	UniProtKB	Natural variant	948	948	.	.	.	ID=VAR_053726;Note=S->R;Dbxref=dbSNP:rs34062885	
O14746	UniProtKB	Natural variant	979	979	.	.	.	ID=VAR_062542;Note=In DKCA2%3B shortened telomeres but no effect on telomerase catalytic activity nor on binding to TERC. R->W;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15885610,ECO:0000269|PubMed:16990594,ECO:0000269|PubMed:21602826;Dbxref=dbSNP:rs199422305,PMID:15885610,PMID:16990594,PMID:21602826	
O14746	UniProtKB	Natural variant	1025	1025	.	.	.	ID=VAR_068800;Note=In PFBMFT1. V->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:21436073;Dbxref=PMID:21436073	
O14746	UniProtKB	Natural variant	1062	1062	.	.	.	ID=VAR_025150;Note=Increased incidence in sporadic acute myeloid leukemia. A->T;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15814878,ECO:0000269|PubMed:19147845,ECO:0000269|PubMed:19760749,ECO:0000269|Ref.7;Dbxref=dbSNP:rs35719940,PMID:15814878,PMID:19147845,PMID:19760749	
O14746	UniProtKB	Natural variant	1090	1090	.	.	.	ID=VAR_036870;Note=In PFBMFT1%3B severe. V->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15814878;Dbxref=dbSNP:rs121918664,PMID:15814878	
O14746	UniProtKB	Natural variant	1110	1110	.	.	.	ID=VAR_062543;Note=In idiopathic pulmonary fibrosis susceptibility%3B impaired telomerase activity. T->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17392301;Dbxref=dbSNP:rs199422306,PMID:17392301	
O14746	UniProtKB	Natural variant	1127	1127	.	.	.	ID=VAR_062544;Note=In DKCA2%3B severe%3B shortened telomeres but no effect on telomerase catalytic activity nor on binding to TERC. F->L;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15885610,ECO:0000269|PubMed:16990594;Dbxref=dbSNP:rs1176273130,PMID:15885610,PMID:16990594	
O14746	UniProtKB	Mutagenesis	137	141	.	.	.	Note=Reduced catalytic activity and repeat addition processivity. Complete loss of catalytic activity but no loss of binding to telomeric primers%3B when associated with 930-A--A-934. WGLLL->AAAAA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17296728;Dbxref=PMID:17296728	
O14746	UniProtKB	Mutagenesis	169	169	.	.	.	Note=About 80%25 loss of enzymatic activity. Greatly reduced incorporation of second nucleotide. Altered strength of binding to ssDNA. Little effect on repeat addition processivity%2C nor on TR interaction nor on protein levels. Q->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19777057;Dbxref=PMID:19777057	
O14746	UniProtKB	Mutagenesis	169	169	.	.	.	Note=About 85%25 loss of enzymatic activity. Greatly reduced incorporation of second nucleotide. Altered strength of binding to ssDNA. No effect on protein levels nor on TR interaction. Q->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19777057;Dbxref=PMID:19777057	
O14746	UniProtKB	Mutagenesis	169	169	.	.	.	Note=About 90%25 loss of enzymatic activity. Greatly reduced incorporation of second nucleotide. Altered strength of binding to ssDNA. No effect on protein levels nor on TR interaction. Q->T;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19777057;Dbxref=PMID:19777057	
O14746	UniProtKB	Mutagenesis	457	457	.	.	.	Note=Abolishes phosphorylation by DYRK2. S->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23362280;Dbxref=PMID:23362280	
O14746	UniProtKB	Mutagenesis	547	547	.	.	.	Note=Defective in high-affinity TERC interactions. W->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15082768;Dbxref=PMID:15082768	
O14746	UniProtKB	Mutagenesis	631	631	.	.	.	Note=Abolishes telomerase catalytic activity. R->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17026956;Dbxref=PMID:17026956	
O14746	UniProtKB	Mutagenesis	707	707	.	.	.	Note=Abolishes oxidative stress-induced phosphorylation and RAN binding. Impaired nuclear export and enhanced antiapoptotic activity against ROS-dependent apoptosis induction. Impaired interaction with PTPN11. No dephosphorylation by PTPN11. Y->F;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12808100,ECO:0000269|PubMed:18829466;Dbxref=PMID:12808100,PMID:18829466	
O14746	UniProtKB	Mutagenesis	712	712	.	.	.	Note=Loss of telomerase activity. In the absence of TR%2C no loss of binding to telomeric primers. D->A;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:17026956,ECO:0000269|PubMed:17296728,ECO:0000269|PubMed:9389643,ECO:0000269|PubMed:9443919;Dbxref=PMID:17026956,PMID:17296728,PMID:9389643,PMID:9443919	
O14746	UniProtKB	Mutagenesis	866	866	.	.	.	Note=Moderate reduction in telomerase activity%2C no change in repeat extension rate nor on nucleotide incorporation fidelity. Little further reduction in activity but 13.5-fold increase in nucleotide incorporation fidelity%3B when associated with M-867. L->Y;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17264120;Dbxref=PMID:17264120	
O14746	UniProtKB	Mutagenesis	867	867	.	.	.	Note=About 75%25 reduction in telomerase activity%2C about 80%25 reduction in repeat reduction rate and 3.9-fold increase in nucleotide incorporation fidelity. V->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17264120;Dbxref=PMID:17264120	
O14746	UniProtKB	Mutagenesis	867	867	.	.	.	Note=About 75%25 reduction in telomerase activity%2C about 50%25 reduction in repeat extension rate and 5.2-fold increase in nucleotide incorporation fidelity. Little further reduction in activity and 13.5-fold increase in nucleotide incorporation fidelity%3B when associated with Y-866. V->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17264120;Dbxref=PMID:17264120	
O14746	UniProtKB	Mutagenesis	867	867	.	.	.	Note=Severe reduction in telomerase activity%2C about 50%25 reduction in repeat extension rate and 2.2-fold increase in nucleotide incorporation fidelity. No further reduction in activity but 2.8-fold increase in nucleotide incorporation fidelity%3B when associated with Y-866. V->T;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17264120;Dbxref=PMID:17264120	
O14746	UniProtKB	Mutagenesis	868	869	.	.	.	Note=Loss of telomerase activity. DD->AA	
O14746	UniProtKB	Mutagenesis	868	868	.	.	.	Note=Loss of telomerase activity. D->A;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15082768,ECO:0000269|PubMed:15857955,ECO:0000269|PubMed:17026956,ECO:0000269|PubMed:9389643,ECO:0000269|PubMed:9443919;Dbxref=PMID:15082768,PMID:15857955,PMID:17026956,PMID:9389643,PMID:9443919	
O14746	UniProtKB	Mutagenesis	869	869	.	.	.	Note=Loss of telomerase activity. D->A;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:9389643,ECO:0000269|PubMed:9443919;Dbxref=PMID:9389643,PMID:9443919	
O14746	UniProtKB	Mutagenesis	930	934	.	.	.	Note=Completely abolishes telomerase-mediated primer extension and reduced binding to short telomeric primers. Complete loss of catalytic activity but no further loss of binding to telomeric primers%3B when associated with 137-A--A-141. WCGLL->AAAAA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17296728;Dbxref=PMID:17296728	
O14746	UniProtKB	Sequence conflict	516	516	.	.	.	Note=D->G;Ontology_term=ECO:0000305;evidence=ECO:0000305	
O14746	UniProtKB	Helix	966	983	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5UGW	
O14746	UniProtKB	Helix	984	986	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5UGW	
O14746	UniProtKB	Turn	989	991	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5UGW	
O14746	UniProtKB	Helix	994	1017	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5UGW	
O14746	UniProtKB	Helix	1025	1027	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5UGW	
O14746	UniProtKB	Helix	1029	1050	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5UGW	
O14746	UniProtKB	Turn	1051	1053	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5UGW	
O14746	UniProtKB	Helix	1067	1082	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5UGW	
O14746	UniProtKB	Helix	1083	1085	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5UGW	
O14746	UniProtKB	Helix	1086	1104	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5UGW	
O14746	UniProtKB	Helix	1111	1118	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5UGW	
